HC Wainwright Issues Pessimistic Estimate for UNCY Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Investment analysts at HC Wainwright lowered their Q1 2025 earnings per share (EPS) estimates for Unicycive Therapeutics in a note issued to investors on Tuesday, April 1st. HC Wainwright analyst E. Arce now expects that the company will post earnings per share of ($0.08) for the quarter, down from their prior estimate of ($0.07). HC Wainwright currently has a “Buy” rating and a $7.50 target price on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ Q1 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.35) EPS, FY2025 earnings at ($0.35) EPS, FY2026 earnings at $0.92 EPS, FY2026 earnings at $0.92 EPS, FY2027 earnings at $1.98 EPS, FY2027 earnings at $1.98 EPS, FY2028 earnings at $1.19 EPS and FY2029 earnings at $1.34 EPS.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its earnings results on Thursday, March 27th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.13).

Unicycive Therapeutics Stock Performance

Shares of NASDAQ:UNCY opened at $0.52 on Friday. Unicycive Therapeutics has a 52 week low of $0.20 and a 52 week high of $1.49. The firm has a market cap of $53.55 million, a PE ratio of -0.53 and a beta of 2.26. The firm’s fifty day moving average is $0.58 and its 200-day moving average is $0.57.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. XTX Topco Ltd acquired a new stake in shares of Unicycive Therapeutics in the third quarter valued at about $29,000. Virtu Financial LLC boosted its holdings in Unicycive Therapeutics by 566.8% in the third quarter. Virtu Financial LLC now owns 73,975 shares of the company’s stock valued at $30,000 after acquiring an additional 62,881 shares during the last quarter. Northern Trust Corp increased its position in Unicycive Therapeutics by 142.4% during the 4th quarter. Northern Trust Corp now owns 58,181 shares of the company’s stock valued at $46,000 after purchasing an additional 34,183 shares during the period. Geode Capital Management LLC raised its holdings in Unicycive Therapeutics by 30.3% during the 4th quarter. Geode Capital Management LLC now owns 524,487 shares of the company’s stock worth $417,000 after purchasing an additional 122,089 shares during the last quarter. Finally, Acuta Capital Partners LLC lifted its position in shares of Unicycive Therapeutics by 16.4% in the 4th quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company’s stock worth $1,829,000 after purchasing an additional 323,801 shares during the period. 40.42% of the stock is owned by institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.